Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model. (25th September 2020)

• Record Type: Journal Article
• Authors: Voigtlaender, Minna; Beckmann, Lennart; Schulenkorf, Anita; Sievers, Bianca; Rolling, Christina; Bokemeyer, Carsten; Langer, Florian
• Is Part Of: Journal of thrombosis and haemostasis. Volume 18:Number 12(2020)
• Page Start: 3267
• Page End: 3279
• Publication Date: 2020-09-25
• Subjects: low molecular weight heparin -- myeloperoxidase -- prostate cancer -- rivaroxaban -- thrombosis; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.15075
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract: Background: Inflammation with leukocyte activation is a hallmark of cancer‐associated thrombosis (CAT), and elevated leukocytes predict venous thromboembolism in cancer outpatients. In a recent trial, rivaroxaban was more efficacious than dalteparin in preventing CAT recurrence. Objectives: In a proof‐of‐concept study, we aimed to provide a mechanistic basis for improved efficacy of rivaroxaban compared to low molecular weight heparin in CAT treatment. Methods: We studied the effects of rivaroxaban, dalteparin, and tinzaparin at peak and trough levels on tumor cell–induced procoagulant activity and platelet aggregation in the presence or absence of the cationic leukocyte‐derived enzyme, myeloperoxidase (MPO). Furthermore, pro‐inflammatory conditions were generated by stimulating whole blood with lipopolysaccharide (LPS) or phorbol‐myristate‐acetate (PMA), before measuring thrombin generation in plasma supernatants. Results: All three anticoagulants inhibited thrombin generation, fibrin clot formation, and platelet aggregation induced by the tissue factor‐expressing prostate carcinoma cell line, 22Rv1. Pre‐incubation with MPO partially attenuated the anticoagulant activity of dalteparin and tinzaparin, but not rivaroxaban, at trough levels. The effect of MPO did not involve the enzyme's catalytic properties, but required its structural integrity, as indicated by heat denaturation. In plasma obtained from LPS‐ or PMA‐stimulated whole blood, elevated MPO antigen levels inversely correlated with the ability of tinzaparin to inhibit 22Rv1‐induced thrombin generation. Conclusions: Myeloperoxidase release may partially attenuate the anticoagulant activity of trough levels of dalteparin and tinzaparin in the context of paraneoplastic leukocyte activation. However, this effect is likely not sufficient to explain the improved efficacy of rivaroxaban, and possibly other oral factor Xa inhibitors, in CAT treatment.